Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

eTheRNA Immunotherapies N.V.

eTheRNA’s goal is to commercialize mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases. To fight cancer, eTheRNA adopts multiple strategies including :  Immunostimulation Oncolysis Tumor microenvironments (TME) modulation The different approaches can be combined with each other and other classes of treatment interventions. To fight infectious diseases, eTheRNA is adapting its proprietary TriMix technology to a product that can be administered intranasally and lead to antigen-specific T-cell-mediated mucosal immunity. This new approach is being applied to vaccines to protect against upper respiratory tract viruses including CoV-19 (coronavirus). *

 

Period Start 2020-06-16 renamed before
  Group eTheRNA (Group)
  Predecessor eTheRNA BVBA
Products Industry microRNA (miRNA) technology
  Industry 2 lipid nanoparticle technology (LNP technology)
Persons Person Powell, Steven (eTheRNA CEO 202006 before Macrophage Pharma 201705 CEO)
  Person 2 Greig, Russell G. (Greig Biotechnology Global Consulting before 30y at GSK most recently President of SR One)
     
Region Region Belgium_oo
  Country Belgium
  Street 10 Galileilaan
  City 2845 Niel
  Tel +32-3-369-1740
    Address record changed: 2020-12-02
     
Basic data Employees A: 1 to 10 (2016-03-05)
     
    �About Section� taken from web site of organisation on 21.06.
     
   
Record changed: 2020-08-04

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for eTheRNA (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top